A sensitive assay to measure biomarker glycosylation demonstrates increased fucosylation of prostate specific antigen (PSA) in patients with prostate cancer compared with benign prostatic hyperplasia

Clinica Chimica Acta

Volumn 411, Issue 23-24, 2010, Pages 1935-1939

  Dwek, Miriam V ^a   Jenks, Andrew ^a   Leathem, Anthony J C ^b  

^a UNIVERSITY OF WESTMINSTER   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Enzyme linked immunosorbent assay (ELISA); Enzyme linked lectin assay (ELLA); Fucosylation; Glycosylation; Lectin; Prostate specific antigen (PSA)

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; ULEX EUROPAEUS AGGLUTININ;

ADULT; AGED; ARTICLE; BINDING AFFINITY; BLOOD SAMPLING; CLINICAL ARTICLE; COLORIMETRY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FUCOSYLATION; GLYCOSYLATION; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BINDING; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BLOOD CHEMICAL ANALYSIS; FUCOSE; GLYCOSYLATION; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; PLANT LECTINS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

ULEX EUROPAEUS;

EID: 77957750584     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.08.009     Document Type: Article

References (25)

1. Henttu P., Vihko P. cDNA coding for the entire human prostate specific antigen shows high homologies to the human tissue kallikrein genes. Biochem Biophys Res Commun 1989, 160:903-910.
2. Belanger A., van Halbeek H., Gravees H.C., et al. Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate 1995, 27:187-197.
3. Benson M.C., Whang I.S., Pantuck A., et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol. 1992, 147:815-816.
4. Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992, 267:2215-2220.
5. Thiel R.P., Oesterling J.E., Wojno K.J., et al. Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology 1996, 48:S45-S50.
6. Christensson A., Bjork T., Nilsson O., et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993, 150:100-105.
7. Bangma C.H., Kranse R., Blijenberg B.G., Schroder F.H. The value of screening tests in the detection of prostate cancer. Part II: retrospective analysis of free/total prostate-specific analysis ratio, age-specific reference ranges, and PSA density. Urology 1995, 46:779-784.
8. Dwek M.V., Brooks S.A. Harnessing changes in cellular glycosylation in new cancer treatment strategies. Curr Cancer Drug Targets 2004, 4:425-442.
9. Soderstrom K.O. Lectin binding to prostatic epithelium. Cancer 1987, 60:1823-1831.
10. Tangiguchi J., Moriyama N., Nagase Y., Kurimoto S., Kawabe K. Histochemical study of biotinylated lectins in prostate cancer. Nippon Hinyokika Gakkai Zasshi 1995, 86:1008-1015.
11. Arenas M.I., Romo E., de Gaspar I., et al. A lectin histochemistry comparative study in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma. Glycoconj J. 1999, 16:375-382.
12. Abel P.D., Leathem A., Aylott A., Marsh A., Henderson D., Williams G. Carbohydrate residues in non-malignant epithelium as revealed by lectins. Urol. Res. 1987, 15:173-176.
13. Peracaula R., Tabares G., Royle L., et al. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003, 13:457-470.
14. Tabares G., Radcliffe C.M., Barrabes S., et al. Different glycan structures in prostate specific antigen from prostate cancer sera in relation to seminal plasma PSA. Glycobiology 2006, 16:132-145.
15. Meany D.L., Zhang Z., Sokoll L.J., Zhang H., Chan D.W. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation. J Proteome Res. 2009, 8:613-619.
16. Kuno A., Kato Y., Matsuda A., et al. Focused differential glycan analysis with the platform antibody-assisted lectin profiling for glycan-related biomarker validation. Mol Cell Proteomics 2009, 8:99-108.
17. Gornik O., Lauc G. Enzyme linked lectin assay (ELLA) for direct analysis of transferrin sialylation in serum samples. Clin Biochem 2007, 40:718-723.
18. Afrough B., Dwek M.V., Greenwell P. Identification and elimination of false-positives in an ELISA-based system for qualitative assessment of glycoconjugate binding using a selection of plant lectins. Biotechniques 2007, 43(4):458-460.
19. Jankovic M.M., Kosanovic M.M. Glycosylation of urinary prostate-specific antigen in benign hyperplasia and cancer: assessment by lectin binding patterns. Clin Biochem 2005, 38:58-65.
20. Fukushima K., Satoh T., Baba S., Yamashita K. Alpha1, 2-fucosylated and beta-N-acetylgalactosaminylated prostate-specific antigen as an efficient marker of prostatic cancer. Glycobiology 2010, 20(4):452-460.
21. Basu P.S., Majhi R., Batabyal S.K. Lectin and serum-PSA interaction as a screening test for prostate cancer. Clin Biochem 2003, 36:373-376.
22. van Dieijen-Visser M.P., van Pelt J., Delaere K.P. Pitfalls in the differentiation of N-glycosylation variants of prostate-specific antigen using concanavilin A. Eur J Clin Chem Clin Biochem 1994, 32:473-478.
23. Tajiri M., Ohyama C., Wada Y. Oligosaccharide profiles of the prostate specific antigen in free and complexed forms from the prostate cancer patient serum and in seminal plasma: a glycopeptide approach. Glycobiology 2008, 18:2-8.
24. Sarrats A., Comet J., Tabarés G., et al. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis. Prostate 2010, 70(1):1-9.
25. Samadi A.A., Davidson S.D., Mordente J.A., et al. Differential glycosylation of cellular prostate specific antigen and the regulatory mechanism of its secretion. Mol Urol 1999, 3:147-152.